Biologically Focused Therapy of Treatment-Refractory MDS Patients

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Official Title

Biologically Focused Therapy of Treatment Refractory MDS Patients

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. * Provide informed consent;* Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification* Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy* Cytogenetics reported
Exclusion Criteria:
  1. * Hypoplastic MDS* Patients without adequate marrow samples for ex vivo analysis


Peter Greenberg
Peter Greenberg
Professor of Medicine (Hematology), Emeritus

Contact us to find out if this trial is right for you.


Jack Taw